Which systemic therapy would you use to treat a poorly-differentiated round cell sarcoma with CIC-DUX4 gene fusion?
CIC-DUX4 fusion sarcoma is a rare entity, the aggressiveness of which is comparable to Ewing's sarcoma. A major dilemma is whether to treat these patients with Ewing's like regimen (VDC/IE) or generic sarcoma regimen (AIM).
Answer from: Medical Oncologist at Academic Institution
A patient with a sarcoma such as this should be evaluated at a multidisciplinary sarcoma center, including pathology review. I would favor treating with a Ewing sarcoma regimen as these can be very aggressive tumors. A small series recently reported at the annual CTOS meeting of CIC rearranged small...
Comments
Medical Oncologist at Agnesian Cancer Center Thank you Dr Wagner for your response. Since this ...
Thank you Dr Wagner for your response. Since this ...